Saturday, April 27, 2019

FDA approves expanded label for Regeneron/Sanofi's cholesterol drug

The U.S. Food and Drug Administration on Friday approved Regeneron Pharmaceuticals Inc's cholesterol drug Praluent as a treatment to cut the risk of heart attacks, stroke and other major cardiovascular events.


from Reuters: Health https://reut.rs/2WhhLN2

No comments: